Strangvac® is a vaccine against equine strangles, a highly contagious infectious disease that affects horses globally. Strangvac has been granted Marketing Authorisation within the European Union since the 16th of August 2021 and within the UK since the 17th of September 2021.
Strangvac®, consisting only of soluble recombinant proteins, is injected intramuscularly and totally devoid of any living infectious agent.
Innovative technology offers new opportunities
The vaccine has been developed with an innovative technology and is based on fusions of recombinant proteins. The research behind the vaccine’s technical platform has been done together with researchers at Karolinska Institute and the Swedish University of Agricultural Sciences, SLU.
The Marketing Authorisation for Strangvac® is based on a successful series of clinical trials demonstrating the safety, immune response, efficacy and DIVA capability. DIVA (Differentiation of Infected from Vaccinated Animals) capability is a key feature during epidemics in order to distinguish vaccinated animals from asymptomatic carriers.